* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Five Prime Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, Five Prime Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Five Prime Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Five Prime Therapeutics's EV-to-EBIT falls into.
Five Prime Therapeutics's current Enterprise Value is $1,529.91 Mil.
Five Prime Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Five Prime Therapeutics (NAS:FPRX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Five Prime Therapeutics's Enterprise Value for the quarter that ended in Dec. 2020 was $540.06 Mil.
Five Prime Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Five Prime Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Five Prime Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Five Prime Therapeutics (Five Prime Therapeutics) Business Description
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FPRX has been successfully added to your 